echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Targeting Immune Diseases and Cancer $84M to Help Develop SIRP-Targeted Therapies

    Targeting Immune Diseases and Cancer $84M to Help Develop SIRP-Targeted Therapies

    • Last Update: 2022-04-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Electra Therapeutics announced the completion of an $84 million Series B financing to develop innovative therapeutics targeting signaling regulatory proteins (SIRPs)


    Electra is building a pipeline of new therapeutics targeting SIRP


    ▲Electra product pipeline (Image source: Electra's official website)

    ELA026 is a monoclonal antibody specifically designed to treat severe inflammatory diseases with abnormal myeloid and T cell activity


    ▲ Pathological mechanism of sHLH (Image source: Electra official website)

    References:

    [1] Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP‑Targeted Therapies for Immunological Diseases and Cancer.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.